Subtype
Oral Cavity Squamous Cell Carcinoma
CI-CAN-00006183OSCCExplore in graph →
83 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006183OSCCExplore in graph →
Clinical trials
264 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 |
| clinicaltrials |
| NCT07778615 | Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features | completed | — | 34 | Sohag UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT01772706 | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer(LaserMucite) | completed | N/A | 97 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01827956 | Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms(FCR-VADS) | completed | — | 121 | Institut BergoniéOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04725396 | Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC(CURVE) | completed | N/A | 132 | UNICANCEROTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT07015333 | Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab | completed | — | 31 | Commonwealth Healthcare CorporationOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02245100 | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer | completed | — | 130 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03618654 | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | completed | Early Phase 1 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04883645 | Neoadjuvant Imiquimod Immunotherapy for Oral Cancer | completed | Early Phase 1 | 16 | Medical University of South CarolinaOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03459729 | Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | completed | Early Phase 1 | 6 | Medical College of WisconsinOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05950737 | Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience | completed | N/A | 115 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06031337 | Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study | completed | — | 46 | Fayoum UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT03650699 | Biofeedback Rehabilitation to Improve Speaking and Eating in Public(Biofeedback) | completed | N/A | 34 | University Health Network, TorontoOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT05455632 | Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery | completed | — | 192 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01914900 | Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | completed | Phase 2 | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT05708209 | The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124 | completed | — | 40 | Fayoum UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03575598 | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study(SNOW) | completed | Early Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05821179 | Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma | completed | — | 36 | Fayoum UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04413214 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | completed | Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04614896 | Use of Ultrasound for Measuring Size of Oral Tongue Cancers | completed | N/A | 30 | Rigshospitalet, DenmarkOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT03148665 | Saliva-based Detection of CD44(Detect 44) | completed | — | 85 | Joseph CalifanoOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT01636544 | Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity(INECOC) | completed | N/A | 100 | Institut PasteurINDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | completed | Phase 2 | 80 | Gliknik Inc.INDUSTRY | 7 | Mar 8, 2022 | clinicaltrials |
| NCT04059861 | Ultrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin | completed | N/A | 42 | Region Örebro CountyOTHER | 1 | Dec 27, 2021 | clinicaltrials |
| NCT03510390 | Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation(HEAD-MET) | completed | N/A | 17 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT05049408 | Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer | completed | — | 1,160 | S&T Biomed Co., Ltd.INDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01314755 | A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer(IMPACTHN) | completed | N/A | 76 | Terrence JonesOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01254617 | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer(ADCC) | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2020 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials